View Older Stories View More Recent Stories

Mar 4, 2019 08:00AM MilliporeSigma Awarded Canadian CRISPR Nickase Patent for Foundational Genome-Editing Technology
Mar 4, 2019 06:46AM Merck (MRK) Announces EMA Adopts Positive Opinion for its KEYTRUDA for Six-Week Dosing Schedule Across All Current Monotherapy Indications
Mar 4, 2019 06:45AM European Medicines Agency Adopts Positive Opinion for Merck’s KEYTRUDA® (pembrolizumab) for Six-Week Dosing Schedule Across All Current Monotherapy Indications
Mar 1, 2019 08:47AM Merck (MRK) Announces LYNPARZA Received Positive EU CHMP Opinion For Use in Germline BRCA-Mutated HER2-
Mar 1, 2019 08:45AM LYNPARZA® (olaparib) Receives Positive EU CHMP Opinion For Use in Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer
Feb 26, 2019 06:56AM Merck (MRK), AstraZeneca (AZN) Say LYNPARZA Reduced Risk of Disease Progression or Death as First-Line Maintenance Treatment in gBRCAm
Feb 26, 2019 06:55AM LYNPARZA® (olaparib) Reduced the Risk of Disease Progression or Death as First-Line Maintenance Treatment in Germline BRCA-Mutated Metastatic Pancreatic Cancer
Feb 21, 2019 06:45AM Merck (MRK) to Acquire Immune Design (IMDZ) for $5.85/Share
Feb 21, 2019 06:45AM Merck to Acquire Immune Design
Feb 20, 2019 06:46AM Merck (MRK) Says FDA Granted Priority Review to its sBLA for KEYTRUDA Monotherapy for Third-Line Treatment of Patients with Advanced SCLC
Feb 20, 2019 06:45AM FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) Monotherapy for Third-Line Treatment of Patients with Advanced Small Cell Lung Cancer
Feb 19, 2019 04:59PM Merck (MRK) Reports Update on KEYNOTE-240, a Phase 3 Study of KEYTRUDA (pembrolizumab) in Previously Treated Patients with Advanced Hepatocellular Carcinoma
Feb 19, 2019 04:10PM Merck Provides Update on KEYNOTE-240, a Phase 3 Study of KEYTRUDA® (pembrolizumab) in Previously Treated Patients with Advanced Hepatocellular Carcinoma
Feb 19, 2019 08:00AM MilliporeSigma Receives First U.S. Patent for Improved CRISPR Genome-Editing Method
Feb 19, 2019 06:46AM Merck (MRK) Says FDA Approved KEYTRUDA for Adjuvant Treatment of Patients with Melanoma with Involvement of Lymph Node(s) Following Complete Resection
Feb 19, 2019 06:45AM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Adjuvant Treatment of Patients with Melanoma with Involvement of Lymph Node(s) Following Complete Resection
Feb 19, 2019 05:54AM Merck (MRK) Reports Pivotal Phase III Data for BAVENCIO (avelumab) Plus INLYTA (axitinib) in Advanced RCC Published in New England Journal of Medicine (Earlier)
Feb 16, 2019 05:14PM Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine
Feb 16, 2019 05:00PM KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) Reduced Risk of Death by Nearly Half Compared to Sunitinib as First-Line Treatment for Advanced Renal Cell Carcinoma (RCC)
Feb 15, 2019 06:46AM Merck (MRK) Says FDA Granted Priority Review to its sBLA for KEYTRUDA in Combination with Inlyta as First-Line Treatment for Advanced RCC
Feb 15, 2019 06:45AM FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) as First-Line Treatment for Advanced Renal Cel
Feb 14, 2019 06:50AM Merck (MRK) Increases Focus on Advanced Prostate Cancer, Expanding Immuno-Oncology Program with Three New Phase 3 Trials
Feb 14, 2019 06:45AM Merck Increases Focus on Advanced Prostate Cancer, Expanding Immuno-Oncology Program with Three New Phase 3 Trials
Feb 11, 2019 05:45PM EMD Seron, Pfizer (PFE) Announce FDA Accepted sBLA and Granted Priority Review for BAVENCIO Plus INLYTA for Treatment of Advanced RCC
Feb 11, 2019 05:44PM FDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma
Feb 11, 2019 05:03PM Merck (MRK) Highlights Breadth of Immuno-Oncology Research Program in Genitourinary Cancers at ASCO GU
Feb 11, 2019 05:02PM Merck Highlights Breadth of Immuno-Oncology Research Program in Genitourinary Cancers at ASCO GU
Feb 11, 2019 06:46AM Merck (MRK) Says FDA Granted Priority Review to its sBLA for KEYTRUDA for First-Line Treatment of Patients with Recurrent or Metastatic HNSCC
Feb 11, 2019 06:45AM FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Patients with Recurrent or Metastatic Head and Neck Sq
Feb 5, 2019 06:50AM Merck (MRK) Says FDA Accepted for Review NDA for its Investigational Combination of Imipenem/Cilastatin and Relebactam, and sNDA for ZERBAXA
Feb 5, 2019 06:45AM FDA Accepts for Review New Drug Application (NDA) for Merck’s Investigational Combination of Imipenem/Cilastatin and Relebactam, and Supplemental NDA (sNDA) for ZERBAXA® (Ceftolozane and Tazobactam
Feb 4, 2019 06:48AM Merck (MRK) Reports EMA's CHMP Adopts Positive Opinion for Merck’s KEYTRUDA (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Adults with Metastatic Squamous NSCLC
Feb 4, 2019 06:45AM European Medicines Agency Adopts Positive Opinion for Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Adults with Metastatic Squamous Non-Small Cell L
Feb 1, 2019 06:45AM Merck Announces Fourth-Quarter and Full-Year 2018 Financial Results
Jan 30, 2019 06:46AM Merck (MRK) Receives Breakthrough Therapy Designation from FDA for V114 for Prevention of IPD in Children
Jan 30, 2019 06:45AM Merck Receives Breakthrough Therapy Designation from FDA for V114, the Company’s Investigational 15-Valent Conjugate Vaccine for the Prevention of Invasive Pneumococcal Disease, in Infants, Children
Jan 29, 2019 04:31PM Merck (MRK) Reports Election of Mary Ellen Coe to Board
Jan 29, 2019 04:30PM Mary Ellen Coe Elected to Merck Board of Directors
Jan 29, 2019 03:08PM Merck Announces Second-Quarter 2019 Dividend
Jan 22, 2019 06:45AM Merck to Hold Fourth-Quarter and Full-Year 2018 Sales and Earnings Conference Call on February 1
Jan 14, 2019 05:01PM Merck's (MRK) KEYTRUDA Reduced Risk of Death by 31% Compared to Chemotherapy in Previously Treated Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma
Jan 14, 2019 05:00PM Merck’s KEYTRUDA® (pembrolizumab) Reduced Risk of Death by 31 Percent Compared to Chemotherapy in Previously Treated Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tu
Jan 3, 2019 06:53AM Merck (MRK) Announces Five New Approvals for KEYTRUDA (pembrolizumab) in Japan, Including 3 Expanded Uses in Advanced NSCLC
Jan 3, 2019 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Receives Five New Approvals in Japan, Including in Advanced Non-Small Cell Lung Cancer (NSCLC), as Adjuvant Therapy for Melanoma, and in Advanced Microsatellite In
Jan 3, 2019 06:34AM Merck (MRK) Exercises Option to License NGM313, for Treatment of NASH & Type 2 Diabetes
Jan 3, 2019 06:30AM Merck Exercises Option for NGM Bio’s Investigational Insulin Sensitizer, NGM313, for the Treatment of NASH and Type 2 Diabetes
Jan 2, 2019 06:45AM Merck to Participate at the 37th Annual J.P. Morgan Healthcare Conference
Dec 21, 2018 02:06PM UPDATE: Merck KGaA, Pfizer (PFE) to Terminate JAVELIN Ovarian 100 Trial of Avelumab
Dec 21, 2018 02:00PM Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian Cancer
Dec 20, 2018 04:27PM Merck (MRK) Reports Extended Action Date on KEYTRUDA (pembrolizumab) Supplemental Biologics License Application (sBLA) for KEYNOTE-042 Trial
View More Recent Stories View Older Stories